Phase II Trial of Perioperative PD-L1 Inhibition With Avelumab and Docetaxel, Cisplatin and 5-Fluorouracil for Resectable Locally Advanced Esophago-Gastric Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2018
At a glance
- Drugs Avelumab (Primary) ; Cisplatin; Docetaxel; Fluorouracil
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 20 Mar 2018 Planned End Date changed from 1 Aug 2022 to 1 Dec 2023.
- 20 Mar 2018 Planned primary completion date changed from 1 Aug 2020 to 1 Dec 2020.
- 20 Mar 2018 Status changed from not yet recruiting to recruiting.